SIRT3 and acute myeloid leukemia: In AML, SIRT3-driven fatty acid oxidation supports venetoclax resistance in leukemic stem cells; inhibiting SIRT3 with YC8-02 induces lipotoxicity and sensitizes resistant cells while sparing healthy progenitors [140].